- COMT inhibitors are add-on medications used together with levodopa/carbidopa. They do not replace levodopa and are not used on their own.
- The three COMT inhibitors are entacapone, opicapone, and tolcapone. Tolcapone is used much less often because of liver safety concerns.
- By blocking the COMT enzyme, they slow the breakdown of levodopa, so more of it remains available for longer and reaches the brain more steadily.
- They are added when levodopa begins to wear off, and can reduce off time and increase on time — periods when medication is working and movement is better controlled.
COMT inhibitors are medications used in Parkinson’s disease to help levodopa work longer and more consistently. They do not replace levodopa and are not used on their own. Instead, they are added to levodopa/carbidopa when the effect of levodopa wears off too soon or when people experience “off” episodes. The COMT inhibitors used in Parkinson’s include entacapone, opicapone, and tolcapone. They can help reduce motor fluctuations and increase “on” time — periods when Parkinson’s medication is working well and movement symptoms are better controlled.
This article explains what COMT inhibitors are, how they work, when they may be used, which side effects can occur, and what contraindications and precautions people with Parkinson’s should know about.
- Slowing levodopa breakdown before it reaches the brain
- Helping each levodopa dose last longer
- Reducing movement symptoms and wearing off
- Why COMT inhibitors are used only with levodopa
Side effects of COMT inhibitors
- Tolcapone: usually not a first-choice option
Who should not take COMT inhibitors?
- Tolcapone
- Entacapone
- Opicapone
How are COMT inhibitors taken?
When should you talk to your doctor?
Key takeaways: COMT inhibitors in Parkinson’s
What are COMT inhibitors?
COMT inhibitors are a class of Parkinson’s medications that affect how the body processes levodopa. COMT stands for catechol-O-methyltransferase, an enzyme involved in breaking down levodopa before it reaches the brain.
Levodopa is the most important medication for treating the motor symptoms of Parkinson’s disease. Once it reaches the brain, it is converted into dopamine, a chemical messenger that is reduced in Parkinson’s. Dopamine plays a key role in smooth, coordinated movement.
By blocking the COMT enzyme, COMT inhibitors slow the breakdown of levodopa. This allows more levodopa to remain available for longer. As a result, the brain can receive a steadier supply of levodopa, which may help reduce “wearing off” and improve control of motor symptoms such as tremor, bradykinesia, and rigidity.
COMT inhibitors are always used together with levodopa. Without levodopa, they do not meaningfully improve the typical motor symptoms of Parkinson’s.
When are COMT inhibitors used in Parkinson’s?
COMT inhibitors are used as add-on treatment for people with Parkinson’s disease. They are most often considered when a person is taking levodopa and begins to experience motor fluctuations.
Motor fluctuations often develop after longer-term levodopa treatment. A person may notice that each levodopa dose does not last as long as it used to. Symptoms may return before the next dose is due. This is commonly called “wearing off.”
During “off” periods, Parkinson’s symptoms such as slowness, stiffness, tremor, walking problems, or difficulty with daily activities may return or worsen. COMT inhibitors can help some people reduce off time by extending the effect of levodopa.
The goal is to make the medication response smoother and more reliable — not to replace levodopa, but to help it work longer.
Which COMT inhibitors are used for Parkinson’s?
The main COMT inhibitors used in Parkinson’s are:
- Entacapone
- Opicapone
- Tolcapone
All three are used as add-on medications with levodopa. Entacapone and opicapone are used more often in current Parkinson’s treatment. Tolcapone can also be effective, but it is used much less often because of liver safety concerns.
Entacapone is taken with individual levodopa/carbidopa doses to help extend the effect of each dose. It is also available in combination tablets that include levodopa, carbidopa, and entacapone.
Opicapone is taken once daily and is used as add-on treatment with levodopa/carbidopa for people with Parkinson’s who experience off episodes.
Tolcapone is generally reserved for selected situations in which other COMT inhibitors or other treatment options do not work well enough or are not tolerated.
How do COMT inhibitors work?
COMT inhibitors help levodopa work longer and more consistently. They do this by slowing the activity of catechol-O-methyltransferase, or COMT, an enzyme involved in breaking down levodopa in the body.
The practical goal is not to create “more dopamine” in a simple or unlimited way. The goal is to help more levodopa remain available for longer, so each dose can provide a smoother and more sustained effect.
Slowing levodopa breakdown before it reaches the brain
When levodopa is taken by mouth, it travels through the digestive system and bloodstream before reaching the brain. Along the way, enzymes in the body can break some of it down. COMT is one of those enzymes.
By blocking COMT, these medications reduce the conversion of levodopa into a byproduct called 3-O-methyldopa. This can increase the amount of levodopa available to reach the brain, where it can be converted into dopamine.
Helping each levodopa dose last longer
Because more levodopa remains available for longer, COMT inhibitors can help smooth out the medication response. This may be especially helpful when levodopa starts to wear off before the next dose is due.
For some people, this means that Parkinson’s motor symptoms are better controlled between doses. Symptoms such as tremor, slowness of movement, stiffness, and walking difficulty may return less abruptly or less often during the day.
Reducing movement symptoms and wearing off
COMT inhibitors are mainly used when people with Parkinson’s experience motor fluctuations after taking levodopa for some time. These fluctuations can include “off” periods, when medication is not working well and symptoms return or worsen.
By extending the effect of levodopa, COMT inhibitors can reduce off time and increase on time — periods when medication is working and movement is better controlled.
However, this stronger or longer levodopa effect can also increase dyskinesia in some people. Dyskinesia refers to involuntary movements related to dopaminergic treatment. If dyskinesia appears or worsens, the levodopa dose or medication schedule may need to be adjusted.
Why COMT inhibitors are used only with levodopa
COMT inhibitors are not stand-alone Parkinson’s treatments. They do not meaningfully improve Parkinson’s motor symptoms without levodopa.
That is why they are prescribed together with levodopa/carbidopa. Their role is to support levodopa, help it last longer, reduce wearing off, and make the medication response more consistent.
Side effects of COMT inhibitors
Entacapone and opicapone are generally better tolerated than tolcapone and are used more often in current Parkinson’s treatment. Still, side effects can occur with any COMT inhibitor. Some side effects happen because the medication increases or prolongs the effect of levodopa. Others are more specific to the COMT inhibitor itself.
Possible side effects of COMT inhibitors can include:
- Nausea or vomiting
- Headache
- Dyskinesia, or involuntary movements
- Dizziness
- Low blood pressure when standing, also called orthostatic hypotension
- Tiredness or sleepiness, including sudden sleep episodes
- Digestive problems, such as constipation or diarrhea, especially with entacapone or tolcapone
- New or worsening impulse control problems, such as compulsive shopping, sexual behavior, or eating, especially in the context of broader dopaminergic therapy
- Hallucinations
- Confusion or delirium
- Nightmares
- Sleep problems
- Orange, red, or brown urine discoloration, which is usually harmless
- Abnormal liver test results
- Dry mouth
- Lightheadedness or drowsiness
- Sweating
- Muscle twitching
- Liver injury, especially with tolcapone
- Chest pain or angina
- Heart attack, reported occasionally with entacapone
Not everyone experiences these side effects, and they do not occur equally with all COMT inhibitors. Dyskinesia can occur or worsen because levodopa may become more effective or last longer. In that case, the levodopa dose or timing may need to be adjusted.
Tolcapone: usually not a first-choice option
Tolcapone is the oldest of the three COMT inhibitors and is used much less often today. It is generally considered only when entacapone or opicapone do not work well enough or are not tolerated. The main reason is safety: in rare cases, tolcapone can cause serious liver injury.
People who take tolcapone need regular liver monitoring. If liver tests become abnormal, the medication may need to be stopped promptly. The same may apply if severe diarrhea occurs during treatment with a COMT inhibitor.
Who should not take COMT inhibitors?
COMT inhibitors are not right for everyone. Contraindications and precautions differ between entacapone, opicapone, and tolcapone. A neurologist, movement disorder specialist, or pharmacist should review the person’s full medication list, medical history, liver function, psychiatric symptoms, cardiovascular risks, and other health conditions before treatment is started.
Tolcapone
Tolcapone should not be used in people with liver disease, impaired liver function, or abnormal liver enzyme tests. It is also not appropriate for people with a known hypersensitivity to tolcapone or any ingredient in the medication.
Tolcapone should generally be avoided in people with severe dyskinesia, a history of neuroleptic malignant syndrome, a history of rhabdomyolysis, or certain adrenal tumors such as pheochromocytoma.
Because of the risk of serious liver injury, people taking tolcapone need careful monitoring and should follow their doctor’s instructions closely.
Entacapone
Entacapone may not be appropriate for people with a known hypersensitivity to entacapone or any ingredient in the medication. Some formulations may also be unsuitable for people with specific allergies, depending on inactive ingredients.
Entacapone also requires caution or may be contraindicated in people with certain medical histories or medication combinations, including a history of rhabdomyolysis, neuroleptic malignant syndrome, liver disease, impaired liver function, pheochromocytoma, or the use of certain antidepressants or other medications that interact with COMT inhibition.
People with significant heart disease or symptoms such as chest pain should discuss these risks carefully with their treating physician before using entacapone.
Opicapone
Opicapone may not be appropriate for people with a known hypersensitivity to opicapone or any ingredient in the medication.
It is also contraindicated or requires special caution in people with certain catecholamine-secreting tumors, such as pheochromocytoma or paraganglioma, because of the risk of cardiovascular effects. People with a history of neuroleptic malignant syndrome or rhabdomyolysis should also discuss this history with their clinician before treatment.
Because drug interactions and contraindications can differ between medications, people should not assume that one COMT inhibitor can automatically be substituted for another without medical review.
How are COMT inhibitors taken?
COMT inhibitors are taken by mouth and are used together with levodopa/carbidopa.
Entacapone is usually taken with individual levodopa/carbidopa doses. It may be prescribed as a separate tablet or as part of a combination medication.
Tolcapone is typically taken several times per day and requires special safety monitoring because of the risk of liver injury.
Opicapone is taken once daily, usually at bedtime. It should be taken according to the prescribing instructions, including instructions about timing around food and levodopa doses.
The exact dosing schedule depends on the specific medication, the person’s levodopa schedule, symptoms, side effects, other health conditions, and treatment goals.
When should you talk to your doctor?
People with Parkinson’s should talk with their neurologist or movement disorder specialist if they notice that levodopa is not lasting as long as it used to, or if symptoms return before the next dose.
It is especially important to seek medical advice if:
- Off periods are becoming longer or more frequent
- Medication effects feel unpredictable
- Dyskinesia appears or worsens
- Hallucinations, confusion, or vivid dreams develop
- Diarrhea becomes severe or persistent
- Dizziness or low blood pressure causes falls or near-falls
- Sleepiness becomes dangerous, especially while driving
- Impulse control problems appear
- Chest pain, shortness of breath, or other possible heart-related symptoms occur
- There are possible signs of liver problems, such as unusual fatigue, loss of appetite, nausea, dark urine, yellowing of the skin or eyes, or pain in the upper right abdomen
Do not start, stop, or change Parkinson’s medication without medical guidance. Even small changes can affect mobility, off time, dyskinesia, sleep, mood, and daily function.
Key takeaways: COMT inhibitors in Parkinson’s
COMT inhibitors are add-on medications used with levodopa/carbidopa in Parkinson’s disease. They help levodopa last longer and can reduce wearing off and off episodes.
The main COMT inhibitors used in Parkinson’s are entacapone, opicapone, and tolcapone. Entacapone is often taken with levodopa doses. Opicapone is taken once daily. Tolcapone is used much less often because of its risk of serious liver injury.
COMT inhibitors do not work well on their own. Their role is to support levodopa, smooth out medication response, reduce off time, and increase on time.
The right choice depends on the person’s symptoms, medication schedule, side effects, other health conditions, contraindications, and treatment goals. For many people with Parkinson’s, COMT inhibitors can be an important part of managing motor fluctuations — but they need to be used thoughtfully and monitored carefully.